Document is current
Any future updates will be listed below
-
Authors
Arranz, Javier
Ferrer, Rosa
Zhu, Nuole
Rubio-Guerra, Sara
Rodríguez-Baz, Íñigo
Arriola-Infante, José Enrique
Maure-Blesa, Lucía
Garcia-Castro, Jesús
Selma-González, Judit
Carmona-Iragui, María
Barroeta, Isabel
Illán-Gala, Ignacio
Santos-Santos, Miguel
Fortea, Juan
Lleó, Alberto
Tondo, Mireia
Alcolea, Daniel
-
Funding
Funding for this research was provided by:
Instituto de Salud Carlos III through the Río Hortega Fellowship (CM21/00243)
Instituto de Salud Carlos III through the Río Hortega Fellowship (CM22/00052)
Instituto de Salud Carlos III through the Río Hortega Fellowship (CM22/00219)
Instituto de Salud Carlos III through the Río Hortega Fellowship (CM23/00291)
Instituto de Salud Carlos III through the Río Hortega Fellowship (CM23/00176)
Alzheimer’s Association (AARG-22-973966)
Global Brain Health Institute (GBHI_ALZ-18-543740)
Societat Catalana de Neurologia (Premi Beca Fundació SCN 2020)
Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI22/00785, PI19/00882, PI18/00435, PI21/00791, PI22/00611, INT19/00016, INT23/00048, PI17/01896, PI24/00598 and AC19/00103)
Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI22/00785, PI19/00882, PI18/00435, PI21/00791, PI22/00611, INT19/00016, INT23/00048, PI17/01896, PI24/00598 and AC19/00103)
Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI22/00785, PI19/00882, PI18/00435, PI21/00791, PI22/00611, INT19/00016, INT23/00048, PI17/01896, PI24/00598 and AC19/00103)
Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI22/00785, PI19/00882, PI18/00435, PI21/00791, PI22/00611, INT19/00016, INT23/00048, PI17/01896, PI24/00598 and AC19/00103)
Fondo Investigaciones Sanitario (FIS), Instituto de Salud Carlos III (PI21/00791, PI14/01126, PI17/01019, PI20/01473, PI13/01532, PI16/01825, PI18/00335, PI22/00785, PI19/00882, PI18/00435, PI21/00791, PI22/00611, INT19/00016, INT23/00048, PI17/01896, PI24/00598 and AC19/00103)
National Institutes of Health (1R01AG056850-01A1; R21AG056974; and R01AG061566)
National Institutes of Health (1R01AG056850-01A1; R21AG056974; and R01AG061566)
National Institutes of Health (1R01AG056850-01A1; R21AG056974; and R01AG061566)
CIBERNED program (Program 1, Alzheimer Disease)
CIBERNED program (Program 1, Alzheimer Disease)
Fondo Europeo de Desarrollo Regional, Unión Europea, “Una manera de hacer Europa
Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408)
Generalitat de Catalunya (2017-SGR-547, SLT006/17/125, SLT006/17/119, SLT002/16/408)
Fundació Bancaria La Caixa
Fundació Catalana Síndrome de Down
Jérôme Lejeune Foundation
Instituto de Salud Carlos III (INT21/00073, PI20/01473 and PI23/01786)
National Institutes of Health grants (R01 AG056850; R21 AG056974, R01 AG061566, R01 AG081394 and R61AG066543 and 1RF1AG080769-01)
Fundación Tatiana Pérez de Guzmán el Bueno (IIBSP-DOW-2020-151)
Horizon 2020–Research and Innovation Framework Programme from the European Union (H2020-SC1-BHC-2018-2020)
Brightfocus
Life Molecular Imaging
Fundació la Marató de TV3 (20141210, 044412 and 20142610)
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 3 June 2025
First Online: 5 July 2025
Declarations
:
: D.A. participated in advisory boards from Fujirebio-Europe, Roche Diagnostics, Grifols S.A. and Lilly, and received speaker honoraria from Fujirebio-Europe, Roche Diagnostics, Nutricia, Krka Farmacéutica S.L., Zambon S.A.U., Neuraxpharm, Alter Medica, Lilly and Esteve Pharmaceuticals S.A. D.A. declares a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). JA reported receiving personal fees for service on educational activities from Lilly, Esteve, Fujirebio-Europe and Roche diagnostics. S.R.-G. received honoraria from Esteve Pharmaceuticals S.A. for educational activities AL declare a filed patent application (WO2019175379 A1 Markers of synaptopathy in neurodegenerative disease). AL has served as a consultant or on advisory boards for Almirall, Fujirebio-Europe, Roche, Biogen, Grifols, Novartis, Eisai, Lilly, and Nutricia, outside the submitted work. JF reported serving on the advisory boards, adjudication committees, or speaker honoraria from AC Immune, Adamed, Alzheon, Biogen, Eisai, Esteve, Fujirebio, Ionis, Laboratorios Carnot, Life Molecular Imaging, Lilly, Lundbeck, Novo Nordisk, Perha, Roche, Zambón, Spanish Neurological Society, T21 Research Society, Lumind foundation, Jérôme-Lejeune Foundation, Alzheimer’s Association, National Institutes of Health USA, and Instituto de Salud Carlos III. JF reports holding a patent for markers of synaptopathy in neurodegenerative disease (licensed to ADx, EPI8382175.0). No other competing interests were reported. MCI participated in an advisory board from Roche Diagnostics an dreceived speaker honoraria from Roche Diagnostics, Neuraxpharm, Lilly, Esteve Pharmaceuticals S.A and Adium Pharma.
